The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q4 2017 call → NOWe need to determine if management conveys that the reported results for the period (Q4 2017 and full year 2017) do not represent the business the company is actually running today. The question asks: does management repeatedly or substantially indicate that the just-reported numbers describe a company that has already been left behind by what is now actually happening inside the business? We need to look for evidence in the transcript. Management discusses various initiatives, partnerships, J&J collaboration, CMS reimbursement efforts, clinical trials, etc. They also provide guidance for 2018. The key is whether they explicitly say that the reported period's results are stale relative to current operations. For example, they might say that the J&J partnership began late in the period and contributed little, but now it's ramping up. Or they might say that the business is currently running at a higher pace than the reported figures. Let's scan the transcript. Dave Stack says: "Throughout 2017 you could not open a newspaper... The only single administration long acting local analgesic for post-surgical pain, EXPAREL, is uniquely positioned... We are pleased with the significant progress Pacira made during 2017, as we continue to advance our mission... In addition to our own dedicated internal initiatives, we have forged several meaningful partnerships... Our robust partnership with J&J continues to gain traction and helped accelerate EXPAREL daily growth to 10% for the fourth quarter of 2017." That's about the reported period. Later, Charlie Reinhart gives guidance for 2018: "We are guiding to total EXPAREL net product sales of between $300 million and $310 million in 2018. This range aligns with our 2017 year-over-year average daily growth rates recorded during each quarter, ranging from 6% to 10%." So they are guiding to similar growth rates. That doesn't suggest a gap. But then Dave Stack says: "I think the guidance, we believe – well, we hope is conservative. I think as Charlie outlined, we have not done a good job over the last couple of years of making sure that we've met the guidance that we put out there, so we wanted to be appropriately conservative to make sure that we're providing a number to the marketplace that we'll be able to revise upward as the year goes on. But I think Charlie's context was also important.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.